Results of rectal cancer treatment
Background: In Slovenia the incidence of colorectal cancer is growing rapidly. In 2000 591 new cases of colon cancer and 503 new cases of rectal cancer were registered. Our study compares results of two groups of patients with rectal cancer.
Methods: In the period from January 1, 1991, to December 31, 2000, 528 patients with rectal carcinoma underwent resection. We divided them in two groups, one operated in the first 5-year and the other in later 5-year period. 5-year survival was estimated by means of Kaplan-Meier statistical analysis. Patients who died within 30 days after the operation were censored. Differences in survival curves between both groups were assessed by the log rank test.
Results: We resected 528/591 (90.6 %) patients. R0 resection was performed in 431 (81.6 %) patients, R1 in 13 (2.5 %), and R2 in 84 (15.9 %) patients. Postoperative mortality rate in resected patients was 3.6 % (19/528), in the group with paliative operations was 12.7 % (7/55). Overall five-year survival rate was 52.4 % for rectal cancer. Five-year survival rate for the patients with radical resection (R0) was 59.5 %.
Conclusions: 5-year survival for R0-resected patients with rectal cancer was in the period from 1996 to 2000 statistically significantly better compared with the period from 1991 to 1995 (63 % vs. 55 %) (p = 0.03627) in stage III (p = 0.01663).
Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. UICC TNM Atlas. 4th ed. Berlin: Springer; 1997.
Pompe-Kirn V, Zakotnik B, Volk N, Benulič T, Škrk J. Preživetje bolnikov z rakom v Sloveniji (Cancer patients survival in Slovenia) 1963–1990. Onkološki inštitut, Ljubljana 1995.
Incidenca raka v Sloveniji. Poročilo Registra raka za Slovenijo. Št. 22–42. Onkološki inštitut. Ljubljana, 1984–2003.
Wingo PA, Ries LA, Rosemberg HM, Miller DS, Edwards BK. Cancer incidence and Mortality, 1973 1995: a report card for the U. S. Cancer 1998; 82: 1197–207.
Ries LA, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1996, NIH Publ. No. 99-2789. Bethesda: National Cancer Institute, 1999: 164–84.
Wu JS, Fazio VW. Colon cancer. Dis Colon Rectum 2000; 43: 1473– 86.
Omejc M, Štor Z, Juvan R, Jelenc F, Repše S. Colorectal cancer in Slovenia at the turn of the century. Eur Surg 2004; 36/6: 356–9.
Repše S, Štor Z, Juvan R. Kirurgija raka širokega črevesa in danke v Sloveniji. In: Repše S ed. Kirurgija širokega črevesa in danke, Kirurška šola, Kirurške klinike KC, Ljubljana 1996; 118–26.
Wibe A, Moller B, Norstein J, et al. A national strategic change in treatment policy for rectal cancer – implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857–66.
Andersen AE, Tretli S, Coleman MP, Langmark F, Grotmal T. Colorectal cancer survival trends in Norway 1958–1997. Eur J Cancer 2004; 40: 734–42.
Horn A, Morild I, Dahl O. Tumor shrinkage and down staging after preoperative radiation of rectal adenocarcinoma. Radiother Oncol 1990; 18: 19–28.
Heald JR, Moran JB, Ryall RDH, Sexton, MacFerlan JK. Rectal cancer: The Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg. 1998; 133: 894–9.
Church JM, Gibbs P, Chao MW, Tjandra JJ. Optimizing the outcome for patients with rectal cancer. Dis Colon Rectum 2003; 46: 389–402.
Wils J, O’Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspective. Ann Oncol 2001; 12: 13–22.
De Hass-Kock DF, Baeten CG, Jager JJ. Prognostic significance of radial margins of clearence in rectal cancer. Br J Surg 1996; 83: 781–5.
Anonymus. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980–7.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Duch colorectal cancer group. Preoperative radiotherapy combined with total mesorectal excision for respectable rectal cancer. N Engl Med 2001; 345: 638–46.
Trotti A, Byhart R, Stetz J, Gvede C, Com B, Fu K, et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13–47.
Minsky BD. Adjuvant therapy for rectal cancer. Semin Oncol 1999; 26: 540–44.
Markovič S, Benulič T, Čalič M, Koželj M, Lamovec J, Repše S. Rak širokega črevesa in danke. In: Repše S, ed: Priporočila za celostno obravnavo bolnikov z rakom prebavil. Ljubljana: Ministrstvo za zdravstvo R Slovenije, 1997. p. 23–32.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–40.
Coleman MP, Gatta G, Verdecchi A, Esteve J, Sant M, Storm H, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14 Suppl 5: 128–49.
Norčič G, Repše S, Pompe-Kirn V. Rak debelega črevesa in danke v Sloveniji – razlike v kirurškem zdravljenju in preživetju bolnikov. Zdrav Vestn 2005; 74: 767–70.
Repše S, Jelenc F, Štor Z, Omejc M, Juvan R. Kirurgija raka debelega črevesa in danke v Sloveniji v obdobju 1995–2005. In: Repše S, ed. Kirurgija debelega črevesa in danke – standardi in novosti. Kirurška šola, Ljubljana: Kirurške klinike KC; 2006. p. 3– 13.
Berrino F, Capocaccia R, Coleman MP, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003; 14 Suppl 5: v1–v155.
Herbst F, Widder J, Maier A. Diagnosis and therapy of rectal cancer. Eur Surg 2006; 38: 129–34.
Piso P, Dahlke MH, Mirena P, Schmidt U, Aselman H, Schlitt JH, et al. Total mesorectal excision for middle and lower rectal cancer: A single institution experience with 337 consecutive patients. J Surg Oncol 2004; 86: 115–21.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.